The Virtual Human Platform has been developed using three example case studies, which function as a proof of concept.
For each case study, two exemplary regulatory questions were formulated to show how the platform can be used for a step-by-step human-based risk assessment.
To study kidney disease and pharmacovigilance.
To study life course pesticide exposure and neurodegenerative disease.
To study health effects discriminated by age and sex on thyroid-mediated neurodevelopment.
The Virtual Human Platform implements the generic risk assessment workflow as a process flow comprising of five steps. For more information regarding the process flow, visit our process flow info page.
.